NED Axol Biosciences, NovalGen. Chairman Concinnity Genetics. Former President of AskBio Europe; CEO at Synpromics, Anatara Lifesciences and Ark Therapeutics. Founding leadership team NightStar Therapeutics. Honorary Professor, Edinburgh University.
Former Coordinator of the European Stem Cell Bank; Senior Research Fellow at Pfizer; Chief Science Officer of Stem Cell Sciences plc
Former Group Leader at King’s College London, Department of Medical and Molecular Genetics. Extensive expertise in gene editing and RNAi technology research.
Former Financial Controller and Company Secretary Acacia Pharma Group, Senior Audit Manager PwC.
Former CSO at Oxgene; Research management at Cellinta, Lonza, Novozymes. Extensive expertise in the gene therapy and gene editing sector.
Former VP People at Tropic Biosciences, former HR Leader at Horizon Discovery (now Reevity), and United Nations Environment Programme.
Former Research Fellow, University of Queensland
Former Director of Immunology, Owkin; Director, Oncology Cell Therapy, GSK; Senior Scientist, Horizon Discovery
Non-exec director and treasurer, ELRIG. Former Head of Immunology Services and R&D, Revvity
Senior Independent Director of BioCity and Acacia Pharma, and former Chairman of Cell and Gene Therapy Catapult and Synpromics.
Previous board roles include Chairman of Axis-Shield, Chairman of BTG, Non-executive Director of Vectura and Chief Executive Officer of Acambis.
CEO Tropic Biosciences. Experienced AgriTech entrepreneur and investor, who is deeply passionate about utilizing cutting-edge technologies in solving real world challenges.
Investor Director, Calculus Capital. Board member, MIP Discovery, Tagomics, Invizius. 20 years experience in life science investing. Founding team Klein-Edmonds Associates.
NED Axol Biosciences, NovalGen. Chairman Concinnity Genetics. Former President of AskBio Europe; CEO at Synpromics, Anatara Lifesciences and Ark Therapeutics. Founding leadership team NightStar Therapeutics. Honorary Professor, Edinburgh University.
